Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides
Open Access
- 1 January 2009
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 15 (15), 1805-1808
- https://doi.org/10.3748/wjg.15.1805
Abstract
Nitazoxanide, the first thiazolide, was originally developed for the treatment of Cryptosporidium parvum. More recently, antiviral activity of nitazoxanide against hepatitis B virus (HBV) and hepatitis C virus was recognized in in vitro systems. These basic studies led to phase II clinical trials that demonstrated the safety and efficacy of nitazoxanide in combination with peginterferon, with or without ribavirin, in the treatment of chronic hepatitis C genotype 4. The sustained virologic response rate was 79% and 80% in two studies, which was higher than the response rate of 50% with the standard of care with peginterferon plus ribavirin. In very preliminary studies of patients with chronic hepatitis B, nitazoxanide suppressed serum HBV DNA and led to loss of hepatitis B e antigen in the majority of patients and hepatitis B surface antigen in approximately a quarter of patients. Randomized controlled studies of naive and nonresponder patients with chronic hepatitis C genotype 1 are underway, new second generation and controlled release thiazolides are being developed, and future studies of patients with chronic hepatitis B are planned.Keywords
This publication has 8 references indexed in Scilit:
- Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and RibavirinGastroenterology, 2009
- Potential for Hepatitis C Virus Resistance to Nitazoxanide or TizoxanideAntimicrobial Agents and Chemotherapy, 2008
- Thiazolides: A New Class of Drugs for the Treatment of Chronic Hepatitis B and CFuture Microbiology, 2008
- Treatment of Chronic Hepatitis B (CHB) with Nitazoxanide (Ntz) Alone or Ntz Plus Adefovir (ADV) for Two Years with Loss of Hepatitis B E Antigen (HBeAg) and Hepatitis B Surface Antigen (HbsAg)American Journal Of Gastroenterology, 2008
- Clinical trial: randomized, double‐blind, placebo‐controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4Alimentary Pharmacology & Therapeutics, 2008
- 832 EVALUATION OF A 4 WEEK LEAD-IN PHASE WITH NITAZOXANIDE PRIOR TO NITAZOXANIDE+PEGINTERFERON IN TREATING CHRONIC HEPATITIS CJournal of Hepatology, 2008
- Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replicationAntiviral Research, 2007
- NitazoxanideDrugs, 2007